Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The STEP program trials with semaglutide (a GLP-1-only agonist) and the SURMOUNT trials with tirzepatide (dual GIP/GLP-1 agonist) represent the strongest weight loss efficacy data in the history of pharmacotherapy for obesity
The data showed that once-weekly 1 mg doses of semaglutide were shown to reduce the likelihood of a first-time heart failure event, urgent visits or hospitalizations due to heart failure, or cardiovascular death
24 Large molecular size and structural complexity make biologics highly susceptible to degradation by gastric acid and digestive enzymes, leading to loss of activity before absorption can occur
Intramuscular (IM) hydroxocobalamin is the recommended first-line treatment for pernicious anaemia in the UK, as advised by NICE and the British Society for Haematology
This is such an important reminder: GLP-1 therapy can shift physiology, but it cannot replace the foundational habits that protect metabolic health
To address this problem, we propose that existing experimental data can be used to train machine learning (ML) models that are able to extrapolate in sequence space to accurately predict the activity of novel multi-specific peptide analogues
US$ 21.72
US$ 27.29
US$ 25.63
US$ 21.27
US$ 23.43
US$ 20.63
US$ 26.77
US$ 20.85
